


ANTI-INFECTIVE DRUG DISCOVERY & DEVELOPMENT

- ▶ Leading expertise in bacterial, fungal, viral and parasitic diseases and established global network in ID
- ▶ Efficient integration of knowledge, innovation and dedicated platforms – All under one roof
- ▶ Deep understanding of financing landscape for anti-infective discovery and development
- ▶ Seamless transition from Drug Discovery to IND: INDiGO, an Evotec solution



TARGET ID

- ▶ From bioactive hits to Cellular Localisation of Drug-Target Complex (PAL) and Target Binding Site Identification (PAL-MS)
- ▶ Assessment of interaction with the target in living organisms
- ▶ Omics-related technologies for target identification and MoA studies including NGS and WGS

HIT IDENTIFICATION

- ▶ >15 years of expertise in screening, with >30 HTS campaigns in the anti-infective space
- ▶ Phenotypic and target-based HTS
- ▶ BSL 2/2+/3 platform and containment
- ▶ Access to Evotec's compound collections

IN VITRO MICROBIOLOGY

- ▶ EvostrAln™ – Best in class microbiological profiling and characterisation
- ▶ Constantly evolving resource of thousands of primary clinical isolates and reference strains
- ▶ Broad collection of bacteria, fungi, viruses and parasites, obtained from clinics and culture collections

IN VITRO PK/PD: HOLLOW FIBRE SYSTEMS

- ▶ *In vitro* dynamic systems to simulate PK, measure response of pathogen to drug, and potential for emergence of resistance
- ▶ Ability to simulate human drug exposure to confirm target attainment
- ▶ Identification of PD drivers utilising dose fractionation studies
- ▶ Determination of the mutation prevention concentration (MPC) and genotyping of output bacteria

TRANSLATIONAL BIOLOGY: IN VIVO MODELS OF INFECTION AND PK/PD ASSESSMENT

- ▶ Comprehensive *in vivo* pharmacology platform integrating DMPK for PK/PD assessment
- ▶ Multiple hosts and fully validated models of infection, custom design protocols and model development
- ▶ State of the art bioanalytics and biomarker identification

INDiGO: A FASTER, OPTIMISED WAY TO MARKET

- ▶ From drug candidates to clinic as fast as 52 weeks or even less
- ▶ Custom-designed project plans, dedicated Project Managers and leading world-class drug development professionals
- ▶ API route scouting and manufacture, material science, formulation development, clinical supply, safety assessment, DMPK and Bioanalysis including immunoassays
- ▶ GXP certification
- ▶ SEND package and Regulatory support

